Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction.
Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K+ channel blocker has therapeutic potential for acute myocardial infarction.
Takenaka
K
K
Division of Cardiology, Department of Medicine, National Cardiovascular Center, Suita, Osaka, Japan.
Yasuda
S
S
Miyazaki
S
S
Kurita
T
T
Sutani
Y
Y
Morii
I
I
Daikoku
S
S
Kamakura
S
S
Nonogi
H
H
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000592:standards; D004562:Electrocardiography; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000628:therapy; D026902:Potassium Channel Blockers; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000592:standards; D013610:Tachycardia / Q000188:drug therapy; D018754:Ventricular Dysfunction / Q000188:drug therapy* / Q000628:therapy
D000889:Anti-Arrhythmia Agents; D026902:Potassium Channel Blockers; D011744:Pyrimidinones; C076259:nifekalant